Arqule Inc. this week reported a quarterly net loss of $6.4 million, more than the $6.08 million loss a year earlier. But there was good news, too: Arqule will collaborate with the National Human Genome Research Institute on development of ARQ 092 to treat Proteus syndrome, a rare disease characterized by overgrowth of the skeleton, skin, adipose tissue, and central nervous system. Arqule also had positive results in a trial of tivantinib to treat asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.